Back

Revealing the impact of recurrent and rare structural variants in multiple myeloma

Rustad, E. H.; Yellapantula, V. D.; Glodzik, D.; Maclachlan, K. H.; Diamond, B.; Boyle, E. M.; Ashby, C.; Blaney, P.; Gundem, G.; Hultcrantz, M.; Leongamornlert, D.; Angelopoulos, N.; Auclair, D.; Zhang, Y.; Dogan, A.; Bolli, N.; Papaemmanuil, E.; Anderson, K. C.; Moreau, P.; Avet-Loiseau, H.; Munshi, N.; Keats, J.; Campbell, P.; Morgan, G. J.; Landgren, O.; Maura, F.

2019-12-19 genomics
10.1101/2019.12.18.881086 bioRxiv
Show abstract

The landscape of structural variants (SVs) in multiple myeloma remains poorly understood. Here, we performed comprehensive classification and analysis of SVs in multiple myeloma, interrogating a large cohort of 762 patients with whole genome and RNA sequencing. We identified 100 SV hotspots involving 31 new candidate driver genes, including drug targets BCMA (TNFRSF17) and SLAMF7. Complex SVs, including chromothripsis and templated insertions, were present in 61 % of patients and frequently resulted in the simultaneous acquisition of multiple drivers. After accounting for all recurrent events, 63 % of SVs remained unexplained. Intriguingly, these rare SVs were associated with up to 7-fold enrichment for outlier gene expression, indicating that many rare driver SVs remain unrecognized and are likely important in the biology of individual tumors.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.